Breakthrough in Managing Agitated Delirium in Advanced Cancer Patients
A recent study led by researchers at The University of Texas MD Anderson Cancer Center has found that a combination of haloperidol and lorazepam significantly reduces symptoms of agitated delirium in patients with advanced cancers compared to haloperidol alone. Agitated delirium, a distressing condition often seen in end-of-life cancer care, causes patients to exhibit aggressive or abnormal behavior due to deteriorating brain function. The findings were presented at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain.
The RECORD trial, a multi-center study involving 75 adult patients with various cancer types, demonstrated that the combination therapy led to a notable decrease in agitated delirium within 24 hours, as measured by a standard scoring tool. Patients receiving the combination required fewer rescue doses of additional medication compared to those treated with lorazepam alone or placebo. While lorazepam alone also showed some effectiveness, it necessitated more rescue doses, whereas the placebo group saw minimal improvement and required up to five rescue doses.
The study highlights the potential of tailored combination treatments to alleviate distressing symptoms in palliative care settings, offering patients and their families greater comfort during end-of-life care. Adverse effects observed were consistent with the end-of-life process and were not unexpected. This research provides valuable evidence supporting the use of medication to manage agitated delirium, improving quality of life for patients in their final stages of cancer.
All 5 Seasons Of 9-1-1: Lone Star, Ranked
What is Lone Star's best season?
screenrant.com
Frontiers | Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
IntroductionAnxiety diagnoses have surged recently during and after the COVID-19 pandemic. Lorazepam is widely recognized for its efficacy in treatmen
www.frontiersin.org
ESMO: Combination therapy reduced agitated delirium in patients with advanced cancers
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with adva
www.mdanderson.org
Combination reduces agitated delirium among patients with advanced cancers
The addition of lorazepam to haloperidol reduced symptoms of agitated delirium among individuals with advanced cancers, according to study findings.Th
www.healio.com
(PDF) Method Development and Validation of Lorazepam by Using RP-HPLC in Pharmaceutical Formulation
PDF | High pressure liquid chromatography (RP-HPLC) is a column chromatographic technique employing high pressure pump to pass both mobile phase and..
www.researchgate.net
Stroke Survivors Still Prescribed a 'Concerning' Amount of Benzos
Red flag in nationwide data despite improvement since 2013
www.medpagetoday.com
Benzodiazepines Linked to Suicide, Study Finds
A new study finds that benzodiazepines—alprazolam (Xanax), lorazepam (Ativan), and diazepam (Valium)—are associated with an increased risk of suicidal
www.madinamerica.com